Acta Med Okayama

1. KAWADA T, Kobayashi Y, Tsugawa T, Tsuboi K, et al
   Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer.
   Acta Med Okayama. 2025;79:81-92.
   

   >> Share

   
   

   
   Adv Healthc Mater

2. LIU M, Jia G, Meng X, Rong Y, et al
   Cyclic Enrichment of Urinary Exosomes Using a MOF-on-MOF-Based Asymmetric Impinging Streams Chip for Bladder Cancer Diagnosis and Prognosis Prediction.
   Adv Healthc Mater. 2025 Apr 28:e2500848. doi: 10.1002/adhm.202500848.
   

   >> Share

   
   

   
   Ann Diagn Pathol

3. LI W, Wei W, Yuan L, Zhang Y, et al
   Clinicopathological features analysis of Paraganglioma of urinary bladder: A retrospective study.
   Ann Diagn Pathol. 2025;77:152477.
   

   >> Share

   
   

   
   Anticancer Res

4. TUNG CH, Lin SH, Chang KP, Xu YW, et al
   Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep Learning Approaches and Graphical Data Transformation.
   Anticancer Res. 2025;45:1953-1964.
   

   >> Share

   
   
5. FURUBAYASHI N, Mochida M, Kijima A, Fujimoto Y, et al
   Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.
   Anticancer Res. 2025;45:2185-2193.
   

   >> Share

   
   

   
   Asia Pac J Clin Oncol

6. KLEEBAYOON A, Wiwanitkit V
   Change in the Neutrophil-Lymphocyte Ratio and Recurrence in Operated Bladder Cancer.
   Asia Pac J Clin Oncol. 2025 Apr 29. doi: 10.1111/ajco.14183.
   

   >> Share

   
   

   
   Asian Pac J Cancer Prev

7. BIDI SR, Ghagane SC, Rangrez S, Nerli R, et al
   Association of rs2294008 (PSCA) Gene polymorphism in Urothelial Bladder Cancer of South Indian Population.
   Asian Pac J Cancer Prev. 2025;26:1441-1446.
   

   >> Share

   
   

   
   Biomed Pharmacother

8. SHEN CH, Wu JY, Wang SC, Liu HT, et al
   Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo.
   Biomed Pharmacother. 2025;187:118108.
   

   >> Share

   
   

   
   Biomedicines

9. KATAYAMA Y, Akioka T, Kimura S, Fujii M, et al
   Engineered Expression of Hepatocyte Growth Factor Activator Inhibitor-1 (HAI-1) Reduces the Growth of Bladder Cancer Cells.
   Biomedicines. 2025;13:871.
   

   >> Share

   
   

   
   Bladder Cancer

10. YANAGISAWA T, Matsukawa A, Teoh JY, Mori K, et al
    Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates.
    Bladder Cancer. 2025;11:23523735251335122.
    

    >> Share

    
    
11. ZHAO H, Ho VWS, Liu K, Chen X, et al
    Organoid models in bladder cancer: From bench to bedside?
    Bladder Cancer. 2025;11:23523735251330404.
    

    >> Share

    
    

    
    BMC Cancer

12. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    

    >> Share

    
    
13. WANG X, Qu Y, Sun Y, Yang T, et al
    ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling.
    BMC Cancer. 2025;25:789.
    

    >> Share

    
    

    
    Cancer Med

14. HATAKEYAMA S, Taoka R, Miki J, Saito R, et al
    Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy.
    Cancer Med. 2025;14:e70782.
    

    >> Share

    
    

    
    Cancer Prev Res (Phila)

15. KASPERCZYK E, Tarhonska K, Jablonska E
    Epigenetic changes induced by carcinogenic agents or occupational exposure with sufficient evidence for bladder cancer.
    Cancer Prev Res (Phila). 2025 Apr 30. doi: 10.1158/1940-6207.CAPR-24-0450.
    

    >> Share

    
    

    
    Cancer Res Treat

16. TONG Z, Fu G, Zhou F, Liu X, et al
    Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial.
    Cancer Res Treat. 2025 Apr 28. doi: 10.4143/crt.2025.
    

    >> Share

    
    

    
    Cancer Sci

17. MATSUBARA N, Osawa T, Abe T, Oya M, et al
    FGFR2/3 Gene Alterations and Clinical Outcomes in Advanced/Metastatic Urothelial Cancer in Japan: MONSTAR-SCREEN Database Study.
    Cancer Sci. 2025;116:1424-1432.
    

    >> Share

    
    

    
    Cancers (Basel)

18. OYAERT M, Van Praet C, Delrue C, Speeckaert MM, et al
    Novel Urinary Biomarkers for the Detection of Bladder Cancer.
    Cancers (Basel). 2025;17:1283.
    

    >> Share

    
    
19. KATSUMATA H, Koguchi D, Hirano S, Suzuki A, et al
    Association Between CKAP4 Expression and Poor Prognosis in Patients with Bladder Cancer Treated with Radical Cystectomy.
    Cancers (Basel). 2025;17:1278.
    

    >> Share

    
    

    
    Cell Death Dis

20. HUANG J, Lo UG, Wu S, Wang B, et al
    Correction: The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression.
    Cell Death Dis. 2025;16:339.
    

    >> Share

    
    

    
    Cell Death Discov

21. SONG Z, Gui S, Rao X, Zhang G, et al
    TAZ/NRF2 positive feedback loop contributes to proliferation in bladder cancer through antagonistic ferroptosis.
    Cell Death Discov. 2025;11:208.
    

    >> Share

    
    
22. TURDO A, Tulone G, Di Bella S, Porcelli G, et al
    Heightened IDO1 levels predict Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer patients.
    Cell Death Discov. 2025;11:203.
    

    >> Share

    
    

    
    Cells

23. VAKHRUSHEVA O, Zhao F, Markowitsch SD, Slade KS, et al
    Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering Integrins.
    Cells. 2025;14:570.
    

    >> Share

    
    

    
    Clin Cancer Res

24. RODRIGUEZ-MORENO JF, de Velasco G, Alvarez-Fernandez C, Collado R, et al
    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
    Clin Cancer Res. 2025;31:1644-1656.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

25. FRASLIN AM, Benhamou S, Lebret T, Radvanyi F, et al
    Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System Database.
    Clin Genitourin Cancer. 2025;23:102344.
    

    >> Share

    
    
26. NAITO Y, Inoue S, Tochigi K, Shamoto N, et al
    Significance of Body Surface Area Correction for Cisplatin Eligibility Based on Renal Function of Patients With Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2025 Mar 28:102339. doi: 10.1016/j.clgc.2025.102339.
    

    >> Share

    
    

    
    Clin Transl Oncol

27. CHEN C, Fan G, Li P, Yang E, et al
    Comparative study on the efficacy of low-dose and full-dose BCG bladder perfusion therapy.
    Clin Transl Oncol. 2025;27:2174-2190.
    

    >> Share

    
    
28. PUENTE J, Pinto A, Mendez-Vidal MJ, Garcia Del Muro X, et al
    Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain.
    Clin Transl Oncol. 2025;27:2232-2240.
    

    >> Share

    
    

    
    Commun Biol

29. JIN H, Wu P, Lv C, Zhang S, et al
    Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses.
    Commun Biol. 2025;8:689.
    

    >> Share

    
    

    
    Curr Oncol

30. SONG B, Kim D, Ho JN, Le VH, et al
    Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the c-Met/PI3K/Akt Pathway in the Three-Dimensional Bladder Cancer Spheroid Model.
    Curr Oncol. 2025;32:236.
    

    >> Share

    
    
31. SURA S, Bupathi M, Morris V, Conkling P, et al
    Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study.
    Curr Oncol. 2025;32:187.
    

    >> Share

    
    

    
    Curr Oncol Rep

32. POPLI S, Durant AM, Tyson M, Singh P, et al
    Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.
    Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657.
    

    >> Share

    
    

    
    Curr Urol

33. WANG Q, Xu W, Ying L, Shi H, et al
    Erratum: Preliminary study of the mechanism of isolinderalactone inhibiting the malignant behavior of bladder cancer: Erratum.
    Curr Urol. 2025;19:144.
    

    >> Share

    
    
34. WANG Q, Xu W, Ying L, Shi H, et al
    Preliminary study of the mechanism of isolinderalactone inhibiting the malignant behavior of bladder cancer.
    Curr Urol. 2025;19:49-58.
    

    >> Share

    
    
35. O'SULLIVAN NJ, Temperley HC, Corr A, Meaney JFM, et al
    Current role of radiomics and radiogenomics in predicting oncological outcomes in bladder cancer.
    Curr Urol. 2025;19:43-48.
    

    >> Share

    
    

    
    Diseases

36. PORFYRIS O, Detopoulou P, Adamantidi T, Tsoupras A, et al
    Phytochemicals as Chemo-Preventive and Therapeutic Agents Against Bladder Cancer: A Comprehensive Review.
    Diseases. 2025;13:103.
    

    >> Share

    
    

    
    ESMO Open

37. GUPTA S, Climent Duran MA, Sridhar SS, Powles T, et al
    Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.
    ESMO Open. 2025;10:104506.
    

    >> Share

    
    

    
    Eur J Med Res

38. LIU M, Zhang J, Zhu S, Jiang W, et al
    a1,3-mannosyltransferase promotes the malignant progression of bladder cancer through activating TNF signaling pathway.
    Eur J Med Res. 2025;30:353.
    

    >> Share

    
    

    
    Eur Urol

39. DREYER T, Brandt S, Fabrin K, Azawi N, et al
    Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial.
    Eur Urol. 2025 Apr 24:S0302-2838(25)00191-5. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
40. PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al
    Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini, and Andrea Salonia's Letter to the Editor re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and t
    Eur Urol. 2025 Apr 24:S0302-2838(25)00199-X. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
41. ALFRED WITJES J
    Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be Adapted?
    Eur Urol. 2025 Apr 25:S0302-2838(25)00218-0. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Eur Urol Oncol

42. PACKIAM VT, McElree IM, Ghodoussipour S, Nimgaonkar V, et al
    Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bl
    Eur Urol Oncol. 2025 Apr 25:S2588-9311(25)00100.
    

    >> Share

    
    
43. MATSUKAWA A, Cormio A, Miszczyk M, Parizi MK, et al
    Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Eur Urol Oncol. 2025 Apr 26:S2588-9311(25)00043.
    

    >> Share

    
    

    
    Explor Target Antitumor Ther

44. PASCOAL LB, Jalalizadeh M, Barbosa G, da Silva ANMR, et al
    Viral infections and immune modulation in bladder cancer: implications for immunotherapy.
    Explor Target Antitumor Ther. 2025;6:1002311.
    

    >> Share

    
    

    
    Front Immunol

45. WU R, Li D, Zhang S, Wang J, et al
    Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor immune microenvironment and prognostic biomarker.
    Front Immunol. 2025;16:1572108.
    

    >> Share

    
    
46. CAI F, Xu S, Li Y, He Q, et al
    The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities in bladder cancer prognosis.
    Front Immunol. 2025;16:1554829.
    

    >> Share

    
    

    
    Front Pharmacol

47. YUAN Y, Chu G, Ma Q, Liang Z, et al
    Multiscale screening and identifying specific targets for artesunate in suppressing bladder cancer.
    Front Pharmacol. 2025;16:1584502.
    

    >> Share

    
    

    
    Future Oncol

48. STERNSCHUSS M, Rosenberg JE
    Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.
    Future Oncol. 2025;21:1333-1348.
    

    >> Share

    
    

    
    Genes Dis

49. CHEN S, Cheng J, Liu S, Shan D, et al
    Urinary exosomal lnc-TAF12-2:1 promotes bladder cancer progression through the miR-7847-3p/ASB12 regulatory axis.
    Genes Dis. 2024;12:101384.
    

    >> Share

    
    

    
    Indian J Nucl Med

50. VISAKH RA, Raja S, Pratap T, Thomas RM, et al
    Testicular Tuberculosis after Intravesical BCG for Urinary Bladder Cancer: A Role of FDG PET-CT.
    Indian J Nucl Med. 2024;39:460-462.
    

    >> Share

    
    

    
    Indian J Urol

51. TRIPATHY R, Kumar L, Kural S, Thakur A, et al
    The current status of miRNA in urinary bladder cancer: A minireview and strength, weakness, opportunity, and threat analysis.
    Indian J Urol. 2025;41:98-103.
    

    >> Share

    
    
52. AGRAWAL S
    Expanding horizons to cure muscle-invasive bladder cancer: A novel treatment algorithm.
    Indian J Urol. 2025;41:153-154.
    

    >> Share

    
    

    
    Int J Biol Sci

53. HO CY, Hwang TI, Peng PW, Tsai TF, et al
    Antitumor Effects of Sesamin via the LincRNA-p21/STAT3 Axis in Human Bladder Cancer: Inhibition of Metastatic Progression and Enhanced Chemosensitivity.
    Int J Biol Sci. 2025;21:2692-2706.
    

    >> Share

    
    

    
    Int J Environ Res Public Health

54. LYDOM LN, Raffing R, Lauridsen SV, Egerod I, et al
    Perspectives on an Intensive Hospital-Based Smoking Cessation Intervention in Relation to Transurethral Resection of the Bladder Tumour (TURBT): Interviews with Patients, Relatives, and Clinicians.
    Int J Environ Res Public Health. 2025;22:555.
    

    >> Share

    
    

    
    Int J Urol

55. WADA N, Hatakeyama T, Takagi H, Tsunekawa R, et al
    Trends in age and antithrombotic therapy in patients who underwent transurethral resection of bladder tumor and perioperative complications.
    Int J Urol. 2025;32:516-523.
    

    >> Share

    
    
56. YAMADA Y, Taguchi M, Shimatani K, Yanagi T, et al
    The usefulness of transarterial embolization before transurethral resection of bladder tumor for patients with large bladder tumors.
    Int J Urol. 2025;32:488-492.
    

    >> Share

    
    
57. KANNO T, Ito K, Kita Y, Mochizuki T, et al
    Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma.
    Int J Urol. 2025;32:593-597.
    

    >> Share

    
    
58. KOBATAKE K, Goto K, Sakamoto Y, Iwane K, et al
    Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin.
    Int J Urol. 2025;32:524-530.
    

    >> Share

    
    
59. YONEYAMA F, Shinohara M, Kawashima Y, Yoneyama A, et al
    Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
    Int J Urol. 2025 May 1. doi: 10.1111/iju.70087.
    

    >> Share

    
    

    
    Int Urol Nephrol

60. GAO S, Liu T, Liu Q
    DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter.
    Int Urol Nephrol. 2025 May 2. doi: 10.1007/s11255-025-04527.
    

    >> Share

    
    

    
    Investig Clin Urol

61. ZHENG CM, Kang HW, Moon S, Byun YJ, et al
    Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome research in bladder cancer.
    Investig Clin Urol. 2025;66:272-280.
    

    >> Share

    
    
62. SAHIN G, Gemalmaz H, Gok M
    Correlation of shear wave elastography with histopathological grade, tumor stage, and microvessel density in bladder cancer.
    Investig Clin Urol. 2025;66:207-214.
    

    >> Share

    
    

    
    J Biol Chem

63. CHEN H, Na X, Hu P, Ma Q, et al
    WWP1 mediates the ubiquitination and degradation of HIPK3 in bladder cancer cells.
    J Biol Chem. 2025 Apr 23:108528. doi: 10.1016/j.jbc.2025.108528.
    

    >> Share

    
    

    
    J Clin Med

64. TARANTINO G, Imbimbo C, Ferro M, Bianchi R, et al
    Which Surrogate Marker of Insulin Resistance Among Those Proposed in the Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?
    J Clin Med. 2025;14:2636.
    

    >> Share

    
    

    
    J Pers Med

65. SANDBERG M, Whitman W, Bissette R, Ross C, et al
    Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer Cell Line HT-1197.
    J Pers Med. 2025;15:143.
    

    >> Share

    
    

    
    J Pharm Biomed Anal

66. SHEN Y, Wu Y, Yan C, Bi C, et al
    Nanobody-based double antibody sandwich colloidal gold test strips for rapid detection of urinary biomarkers NMP22 and survivin in bladder cancer.
    J Pharm Biomed Anal. 2025;263:116905.
    

    >> Share

    
    

    
    J Transl Med

67. YANG X, Wu X, Hao X, Li T, et al
    Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer.
    J Transl Med. 2025;23:489.
    

    >> Share

    
    

    
    JCI Insight

68. KWEK SS, Yang H, Li T, Ilano A, et al
    Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer.
    JCI Insight. 2025 Apr 29:e177373. doi: 10.1172/jci.insight.177373.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

69. TANEDA Y, Urabe F, Uchida N, Kadena S, et al
    Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study.
    Jpn J Clin Oncol. 2025;55:522-530.
    

    >> Share

    
    

    
    Medicina (Kaunas)

70. KORAK T, Baloglu IH, Kasap M, Arisan ED, et al
    Proteomic and In Silico Analyses Highlight Complement System's Role in Bladder Cancer Immune Regulation.
    Medicina (Kaunas). 2025;61:735.
    

    >> Share

    
    

    
    Medicine (Baltimore)

71. LU Y, Li J, Qin X
    Study on extended-spectrum beta-lactamases genes and drug resistance in patients with urinary tract infection of enterohemorrhagic Escherichia coli after bladder cancer surgery.
    Medicine (Baltimore). 2025;104:e42098.
    

    >> Share

    
    

    
    Minerva Urol Nephrol

72. TONIN E, Bianchi L, Mottaran A, Bronimann S, et al
    Radical cystectomy for bladder cancer in solid organ transplant recipients.
    Minerva Urol Nephrol. 2025;77:202-208.
    

    >> Share

    
    
73. LEONARDI R, Mantica G, Ambrosini F, Calarco A, et al
    The current status of biomarkers for bladder cancer: progress and challenges.
    Minerva Urol Nephrol. 2025;77:149-151.
    

    >> Share

    
    

    
    Nan Fang Yi Ke Da Xue Xue Bao

74. LI Y, Song X, Sun R, Dong X, et al
    [A pan-cancer analysis of PYCR1 and its predictive value for chemotherapy and immunotherapy responses in bladder cancer].
    Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:880-892.
    

    >> Share

    
    

    
    NAR Genom Bioinform

75. COHEN Z, Petrenko E, Barisaac AS, Abu-Zhayia ER, et al
    SLAYER: a computational framework for identifying synthetic lethal interactions through integrated analysis of cancer dependencies.
    NAR Genom Bioinform. 2025;7:lqaf052.
    

    >> Share

    
    

    
    Naunyn Schmiedebergs Arch Pharmacol

76. GAO D, Yin J, Tie P, Liu Q, et al
    Bioinformatics analysis reveals CTSF suppresses tumor cell malignant phenotype and CD8 + T cell exhaustion by downregulating Bcl- 2 protein in the microenvironment of bladder cancer.
    Naunyn Schmiedebergs Arch Pharmacol. 2025.
    

    >> Share

    
    

    
    Pharmaceuticals (Basel)

77. GUO J, Xiong S, Zhang X, Gong W, et al
    Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer.
    Pharmaceuticals (Basel). 2025;18:511.
    

    >> Share

    
    
78. YING L, Chen R, Guo R, Liang Y, et al
    Paeonol Suppresses Bladder Cancer Progression via Apoptotic Pathways: Insights from In Vitro and In Vivo Studies.
    Pharmaceuticals (Basel). 2025;18:472.
    

    >> Share

    
    

    
    Spectrochim Acta A Mol Biomol Spectrosc

79. SARKEES E, Taha F, Oudahmane I, Vuiblet V, et al
    Evaluation of the diagnostic potential of Fourier transform-infrared spectroscopy on urine for urothelial bladder cancer: an in-hospital field study.
    Spectrochim Acta A Mol Biomol Spectrosc. 2025;339:126274.
    

    >> Share

    
    

    
    Urol Int

80. MUNKER KA, Reineke D, Schneidewind L, Mussgens C, et al
    A rare case of a plasmacytoid and sarcomatoid differentiated urothelial bladder carcinoma with a single metastasis to the right ventricle of the heart and rapid review of single heart metastasis in bladder cancer.
    Urol Int. 2025 Apr 26:1-15. doi: 10.1159/000546149.
    

    >> Share

    
    

    
    Urologie

81. UHLIG A
    [Secondary bladder cancer following radiation therapy for prostate cancer: a systematic review and meta-analysis of incidence and outcomes].
    Urologie. 2025 Apr 29. doi: 10.1007/s00120-025-02592.
    

    >> Share

    
    

    
    World J Surg Oncol

82. GAO W
    Current laser application in En bloc resection of bladder tumor- a narrative literature review.
    World J Surg Oncol. 2025;23:165.
    

    >> Share

    
    

    
    World J Urol

83. ERAKY A, Hug B, Ben-David R, Kolanukuduru KP, et al
    Efficacy of Bacillus Calmette-Guerin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer.
    World J Urol. 2025;43:255.
    

    >> Share

    
    
84. RYU H, Lee S, Song SH, Lee H, et al
    Acidic urine as a prognostic factor after intravesical Bacillus Calmette-Guerin induction therapy for nonmuscle-invasive bladder cancer.
    World J Urol. 2025;43:247.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share